FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Haya Lorberboum-Galski

Research Profile

Chemicals & Drugs

Living Beings

Anatomy

Disorders

Adenocarcinoma

Co-author Network

Publications

TOP 3
Rotem Kedar; Michal Licthenstein; Ofra Sabag; Haya Lorberboum-Galski
Soluble CD40 ligand (sCD40L) provides a new delivery system for targeted treatment: sCD40L-caspase 3 chimeric protein for treating B-cell malignancies.
Yitav Glantz; Inna Grodzovski; Michal Lichtenstein; Ofra Sabag; Haya Lorberboum-Galski
Eliminating the six N-terminal amino acids of the caspase 3 large subunit improved production of a biologically active IL2-Caspase3 chimeric protein.
Haya Lorberboum-Galski
Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Haya Lorberboum-Galski (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Rotem Kedar; Michal Licthenstein; Ofra Sabag; Haya Lorberboum-Galski
Soluble CD40 ligand (sCD40L) provides a new delivery system for targeted treatment: sCD40L-caspase 3 chimeric protein for treating B-cell malignancies.
Cancer 2012;118(24):6089-104.
2012: Yitav Glantz; Inna Grodzovski; Michal Lichtenstein; Ofra Sabag; Haya Lorberboum-Galski
Eliminating the six N-terminal amino acids of the caspase 3 large subunit improved production of a biologically active IL2-Caspase3 chimeric protein.
Biotechnology progress 2012;28(2):573-80.
2011: Haya Lorberboum-Galski
Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases.
Expert opinion on drug delivery 2011;8(5):605-21.
2011: Inna Grodzovski; Michal Lichtenstein; Hanan Galski; Haya Lorberboum-Galski
IL-2-granzyme A chimeric protein overcomes multidrug resistance (MDR) through a caspase 3-independent apoptotic pathway.
International journal of cancer. Journal international du cancer 2011;128(8):1966-80.
2011: Matan Rapoport; Lina Salman; Ofra Sabag; Mulchand S Patel; Haya Lorberboum-Galski
Successful TAT-mediated enzyme replacement therapy in a mouse model of mitochondrial E3 deficiency.
Journal of molecular medicine (Berlin, Germany) 2011;89(2):161-70.
2011: Eitan Israeli; Eugenia Yakunin; Yonaton Zarbiv; Amir Hacohen-Solovich; Haya Kisos; Virginie Loeb; Michal Lichtenstein; Tziona Ben-Gedalya; Ofra Sabag; Eli Pikarsky; Haya Lorberboum-Galski; Ronit Sharon
α-Synuclein expression selectively affects tumorigenesis in mice modeling Parkinson's disease.
PloS one 2011;6(5):e19622.
2009: Yuval Sagiv; Ayelet Kaminitz; Haya Lorberboum-Galski; Nadir Askenasy; Shai Yarkoni
A fusion protein composed of IL-2 and caspase-3 ameliorates the outcome of experimental inflammatory colitis.
Annals of the New York Academy of Sciences 2009;1173():791-7.
2009: Michal Irony-Tur-Sinai; Michal Lichtenstein; Talma Brenner; Haya Lorberboum-Galski
IL2-caspase3 chimeric protein controls lymphocyte reactivity by targeted apoptosis, leading to amelioration of experimental autoimmune encephalomyelitis.
International immunopharmacology 2009;9(10):1236-43.
2009: shimon shteingart; M Rapoport; I Grodzovski; O Sabag; M Lichtenstein; R Eavri; Haya Lorberboum-Galski
Therapeutic potency of IL2-caspase 3 targeted treatment in a murine experimental model of inflammatory bowel disease.
Gut 2009;58(6):790-8.
2009: Matan Rapoport; Haya Lorberboum-Galski
TAT-based drug delivery system--new directions in protein delivery for new hopes?
Expert opinion on drug delivery 2009;6(5):453-63.
2008: Matan Rapoport; Ann Saada (Reisch); Orly Elpeleg; Haya Lorberboum-Galski
TAT-mediated delivery of LAD restores pyruvate dehydrogenase complex activity in the mitochondria of patients with LAD deficiency.
Molecular therapy : the journal of the American Society of Gene Therapy 2008;16(4):691-7.
2008: Ann Saada (Reisch); Simon Edvardson; Matan Rapoport; Avraham Shaag; Khaled Amry; Chaya Miller; Haya Lorberboum-Galski; Orly Elpeleg
C6ORF66 is an assembly factor of mitochondrial complex I.
American journal of human genetics 2008;82(1):32-8.
2007: Ronen Eavri; Haya Lorberboum-Galski
A novel approach for enzyme replacement therapy. The use of phenylalanine hydroxylase-based fusion proteins for the treatment of phenylketonuria.
The Journal of biological chemistry 2007;282(32):23402-9.
2005: Michael J Segel; Rami I Aqeilan; Keren Zilka; Haya Lorberboum-Galski; Shulamit B Wallach-Dayan; Michael W Conner; Thomas G Christensen; Raphael Breuer
Effect of IL-2-Bax, a novel interleukin-2-receptor-targeted chimeric protein, on bleomycin lung injury.
International journal of experimental pathology 2005;86(5):279-88.
2005: Michal Lichtenstein; Ahmi Ben-Yehudah; Ruth Belostotsky; Ronen Eaveri; Ofra Sabag; Inna Grodzovski; Haya Lorberboum-Galski
Utilizing a GnRH-based chimeric protein for the detection of adenocarcinoma.
International journal of oncology 2005;27(1):143-8.
2004: R Eaveri; Ahmi Ben-Yehudah; Haya Lorberboum-Galski
Surface antigens/receptors for targeted cancer treatment: the GnRH receptor/binding site for targeted adenocarcinoma therapy.
Current cancer drug targets 2004;4(8):673-87.
2004: Ahmi Ben-Yehudah; Haya Lorberboum-Galski
Targeted cancer therapy with gonadotropin-releasing hormone chimeric proteins.
Expert review of anticancer therapy 2004;4(1):151-61.
2004: Ruth Belostotsky; Haya Lorberboum-Galski
Utilizing Fcepsilon-Bak chimeric protein for studying IgE-FcepsilonRI interactions.
Clinical immunology (Orlando, Fla.) 2004;110(1):89-99.
2003: Vivian Malamud; Ady Vaaknin; Oded Abramsky; Michal Mor; Laurence E Burgess; Ahmi Ben-Yehudah; Haya Lorberboum-Galski
Tryptase activates peripheral blood mononuclear cells causing the synthesis and release of TNF-alpha, IL-6 and IL-1 beta: possible relevance to multiple sclerosis.
Journal of neuroimmunology 2003;138(1-2):115-22.
2003: Ahmi Ben-Yehudah; Rami I Aqeilan; Dana Robashkevich; Haya Lorberboum-Galski
Using apoptosis for targeted cancer therapy by a new gonadotropin releasing hormone-DNA fragmentation factor 40 chimeric protein.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(3):1179-90.
2003: Rami I Aqeilan; Rotem Kedar; Ahmi Ben-Yehudah; Haya Lorberboum-Galski
Mechanism of action of interleukin-2 (IL-2)-Bax, an apoptosis-inducing chimaeric protein targeted against cells expressing the IL-2 receptor.
The Biochemical journal 2003;370(Pt 1):129-40.
2002: Ahmi Ben-Yehudah; Rami I Aqeilan; Ruth Belostotsky; Yehudith Azar; Haya Lorberboum-Galski
Utilizing chimeric proteins for exploring the cellular fate of endogenous proteins.
Biochemical and biophysical research communications 2002;290(1):332-8.
2001: Ruth Belostotsky; Haya Lorberboum-Galski
Apoptosis-inducing human-origin Fcepsilon-Bak chimeric proteins for targeted elimination of mast cells and basophils: a new approach for allergy treatment.
Journal of immunology (Baltimore, Md. : 1950) 2001;167(8):4719-28.
2001: Ahmi Ben-Yehudah; Diana Prus; Haya Lorberboum-Galski
I.V. Administration of L-GNRH-PE66 efficiently inhibits growth of colon adenocarcinoma xenografts in nude mice.
International journal of cancer. Journal international du cancer 2001;92(2):263-8.
2000: Y Azar; Haya Lorberboum-Galski
GnRH-Bik/Bax/Bak chimeric proteins target and kill adenocarcinoma cells; the general use of pro-apoptotic proteins of the Bcl-2 family as novel killing components of targeting chimeric proteins.
Apoptosis : an international journal on programmed cell death 2000;5(6):531-42.
2000: A Fishman; Diana Prus; Ruth Belostotsky; Haya Lorberboum-Galski
Targeted Fc2'-3-PE40 chimeric protein abolishes passive cutaneous anaphylaxis in mice.
Clinical and experimental immunology 2000;119(3):398-403.
1999: Rami I Aqeilan; S Yarkoni; Haya Lorberboum-Galski
Interleukin 2-Bax: a novel prototype of human chimeric proteins for targeted therapy.
FEBS letters 1999;457(2):271-6.
1999: Talma Brenner; I Steinberger; D Soffer; E Beraud; Avraham Ben-Nun; Haya Lorberboum-Galski
A novel antigen-toxin chimeric protein: myelin basic protein-pseudomonas exotoxin (MBP-PE 40) for treatment of experimental autoimmune encephalomyelitis.
Immunology letters 1999;68(2-3):403-10.
1999: Ahmi Ben-Yehudah; S Yarkoni; Amotz Nechushtan; Ruth Belostotsky; Haya Lorberboum-Galski
Linker-based GnRH-PE chimeric proteins inhibit cancer growth in nude mice.
Medical oncology (Northwood, London, England) 1999;16(1):38-45.
1997: I Steinberger; Hannah Ben-Bassat; E Hochberg; Haya Lorberboum-Galski
Interleukin-2 (IL-2) receptor alpha, beta and gamma subunit expression as a function of B-cell lineage ontogeny: the use of IL-2-PE66(4Glu) to characterize internalization via IL-2 receptor subunits.
Scandinavian journal of immunology 1997;46(2):129-36.
1997: Amotz Nechushtan; S Yarkoni; Irina Marianovsky; Haya Lorberboum-Galski
Adenocarcinoma cells are targeted by the new GnRH-PE66 chimeric toxin through specific gonadotropin-releasing hormone binding sites.
The Journal of biological chemistry 1997;272(17):11597-603.
1997: A Fishman; Haya Lorberboum-Galski
Targeted elimination of cells expressing the high-affinity receptor for IgE (Fc epsilon RI) by a Pseudomonas exotoxin-based chimeric protein.
European journal of immunology 1997;27(2):486-94.
1996: S Yarkoni; Michael Lishner; I Tangi; Arnon Nagler; Haya Lorberboum-Galski
B-cell non-Hodgkin's lymphoma: evidence for the t (14;18) translocation in all hematopoietic cell lineages.
Journal of the National Cancer Institute 1996;88(14):973-9.
1996: I Steinberger; Talma Brenner; Haya Lorberboum-Galski
Interleukin 2 pseudomonas exotoxin (IL2-PE66(4)Glu) chimeric protein kills B cells from patients with Myasthenia gravis.
Cellular immunology 1996;169(1):55-61.
1995: I Steinberger; Talma Brenner; Haya Lorberboum-Galski
Interleukin-2 Pseudomonas exotoxin chimeric protein is cytotoxic to B cell cultures derived from myasthenia gravis patients.
Journal of the neurological sciences 1995;133(1-2):183-91.
1995: David BenEzra; G Maftzir; E Hochberg; Irene Anteby; Haya Lorberboum-Galski
Ocular distribution of the chimeric protein IL2-PE40.
Current eye research 1995;14(2):153-8.
1994: Haya Lorberboum-Galski; S Yarkoni; Amotz Nechushtan; J Rachmilewitz; N deGroot; Abraham Hochberg
ABL and BCR genes are not imprinted in androgenetic and gynogenetic human tissues.
Biochemical and biophysical research communications 1994;204(2):621-7.
1994: H D Volk; S Müller; S Yarkoni; T Diamantstein; Haya Lorberboum-Galski
Mechanisms of dichotomous action of IL-2-Pseudomonas exotoxin 40 (IL-2-PE40) on cell-mediated and humoral immune response.
Journal of immunology (Baltimore, Md. : 1950) 1994;153(6):2497-505.
1994: A Amiel; S Yarkoni; Shimon Slavin; R Or; Haya Lorberboum-Galski; Moshe D Fejgin; Arnon Nagler
Detection of minimal residual disease state in chronic myelogenous leukemia patients using fluorescence in situ hybridization.
Cancer genetics and cytogenetics 1994;76(1):59-64.
1994: A Fishman; Y Bar-Kana; I Steinberger; Haya Lorberboum-Galski
Increased cytotoxicity of interleukin 2-pseudomonas exotoxin (IL2-PE) chimeric proteins containing a targeting signal for lysosomal membranes.
Biochemistry 1994;33(20):6235-43.
1991: C P Herbort; MD de Smet; FG Roberge; Robert B Nussenblatt; D FitzGerald; Haya Lorberboum-Galski; Ira Pastan
Treatment of corneal allograft rejection with the cytotoxin IL-2-PE40.
Transplantation 1991;52(3):470-4.
1991: E Beraud; Haya Lorberboum-Galski; Chi-Chao Chan; D FitzGerald; Ira Pastan; Robert B Nussenblatt
Immunospecific suppression of encephalitogenic-activated T lymphocytes by chimeric cytotoxin IL-2-PE40.
Cellular immunology 1991;133(2):379-89.
1991: Haya Lorberboum-Galski; Robert Lafyatis; J P Case; D FitzGerald; Ronald L Wilder; Ira Pastan
Administration of IL-2-PE40 via osmotic pumps prevents adjuvant induced arthritis in rats. Improved therapeutic index of IL-2-PE40 administered by continuous infusion.
International journal of immunopharmacology 1991;13(2-3):305-15.
1990: R W Kozak; Haya Lorberboum-Galski; L Jones; Raj K Puri; M C Willingham; T Malek; David J FitzGerald; Thomas Waldmann; Ira Pastan
IL-2-PE40 prevents the development of tumors in mice injected with IL-2 receptor expressing EL4 transfectant tumor cells.
Journal of immunology (Baltimore, Md. : 1950) 1990;145(8):2766-71.
1990: Haya Lorberboum-Galski; R J Garsia; M Gately; P S Brown; R E Clark; Thomas Waldmann; V K Chaudhary; David J FitzGerald; Ira Pastan
IL2-PE664Glu, a new chimeric protein cytotoxic to human-activated T lymphocytes.
The Journal of biological chemistry 1990;265(27):16311-7.
1989: FG Roberge; Haya Lorberboum-Galski; P Le Hoang; MD de Smet; Chi-Chao Chan; D Fitzgerald; Ira Pastan
Selective immunosuppression of activated T cells with the chimeric toxin IL-2-PE40. Inhibition of experimental autoimmune uveoretinitis.
Journal of immunology (Baltimore, Md. : 1950) 1989;143(11):3498-502.
1989: J P Case; Haya Lorberboum-Galski; Robert Lafyatis; D FitzGerald; Ronald L Wilder; Ira Pastan
Chimeric cytotoxin IL2-PE40 delays and mitigates adjuvant-induced arthritis in rats.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(1):287-91.
1988: M Ogata; Haya Lorberboum-Galski; D FitzGerald; Ira Pastan
IL-2-PE40 is cytotoxic for activated T lymphocytes expressing IL-2 receptors.
Journal of immunology (Baltimore, Md. : 1950) 1988;141(12):4224-8.
1988: Haya Lorberboum-Galski; R W Kozak; Thomas Waldmann; P Bailon; David J FitzGerald; Ira Pastan
Interleukin 2 (IL2) PE40 is cytotoxic to cells displaying either the p55 or p70 subunit of the IL2 receptor.
The Journal of biological chemistry 1988;263(35):18650-6.
1988: Haya Lorberboum-Galski; D FitzGerald; V Chaudhary; Sankar Adhya; Ira Pastan
Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(6):1922-6.